<table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="tbl1" position="float"><object-id pub-id-type="doi">10.7554/eLife.03925.004</object-id><label>Table 1.</label><caption><p>Baseline characteristics of 8390 children tested for malaria using blood film, by survey location</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.03925.004">http://dx.doi.org/10.7554/eLife.03925.004</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"><italic>Characteristic</italic></th><th align="center" colspan="4">Location of survey</th><th align="center" rowspan="2">Overall (n=8390)</th></tr><tr><th align="center">Burkina Faso (n=2821)</th><th align="center">Mozambique (n=2266)</th><th align="center">Rwanda (n=2085)</th><th align="center">Senegal (n=1218)</th></tr></thead><tbody><tr><td>Communities surveyed, n</td><td align="center">537</td><td align="center">607</td><td align="center">490</td><td align="center">371</td><td align="center">2005</td></tr><tr><td colspan="6">(a) Children tested for malaria, n (%)</td></tr><tr><td>&#8195;<italic>Parasitemia</italic></td><td align="center">2821 (99)</td><td align="center">2266 (100)</td><td align="center">2085 (99)</td><td align="center">1218 (99)</td><td align="center">8390 (99)</td></tr><tr><td>&#8195;Positive result among children tested for parasitemia</td><td align="center">&#8195;1696 (60)</td><td align="center">&#8195;578 (25)</td><td align="center">&#8195;16 (0.8)</td><td align="center">&#8195;22 (1.8)</td><td align="center">&#8195;2312 (28)</td></tr><tr><td>&#8195;<italic>P&#402;-HRP-2</italic></td><td align="center">2821 (100)</td><td align="center">na</td><td align="center">2060 (99)</td><td align="center">1217 (99)</td><td align="center">6098 (99)<xref ref-type="table-fn" rid="tblfn1">*</xref></td></tr><tr><td>&#8195;Positive results among children tested for <italic>P&#402;-HRP-2</italic></td><td align="center">&#8195;2051 (73)</td><td align="center">na</td><td align="center">&#8195;35 (1.7)</td><td align="center">&#8195;27 (2.2)</td><td align="center">&#8195;2113 (35)</td></tr><tr><td colspan="6">(b) Type of immunization received, n (%)</td></tr><tr><td>&#8195;<italic>Bacille Calmette Guerin (BCG)</italic></td><td align="center">2799 (99)</td><td align="center">2004 (96)</td><td align="center">2050 (100)</td><td align="center">1160 (98)</td><td align="center">8013 (98)</td></tr><tr><td>&#8195;<italic>Diphtheria&#8211;tetanus&#8211;pertussis (DTP)</italic></td><td align="center">2721 (97)</td><td align="center">2107 (97)</td><td align="center">2055 (98)</td><td align="center">1161 (98)</td><td align="center">8044 (98)</td></tr><tr><td>&#8195;<italic>Measles</italic></td><td align="center">2225 (80)</td><td align="center">1668 (78)</td><td align="center">1727 (86)</td><td align="center">830 (73)</td><td align="center">6450 (80)</td></tr><tr><td>&#8195;<italic>Poliomyelitis</italic></td><td align="center">2810 (100)</td><td align="center">2156 (99)</td><td align="center">2061 (100)</td><td align="center">1204 (100)</td><td align="center">8231 (99)</td></tr><tr><td>&#8195;<italic>Vitamin A</italic></td><td align="center">87 (9.3)</td><td align="center">1554 (87)</td><td align="center">351 (72)</td><td align="center">190 (59)</td><td align="center">2182 (62)</td></tr><tr><td colspan="6">(c) Children's characteristics</td></tr><tr><td>&#8195;<italic>Age in months, median (IQR)</italic></td><td align="center">22 (13&#8211;32)</td><td align="center">20 (13&#8211;31)</td><td align="center">24 (14&#8211;36)</td><td align="center">19 (12&#8211;29)</td><td align="center">22 (13&#8211;32)</td></tr><tr><td>&#8195;<italic>Girls, n (%)</italic></td><td align="center">1347 (48)</td><td align="center">1151 (51)</td><td align="center">1020 (49)</td><td align="center">551 (45)</td><td align="center">4069 (48)</td></tr><tr><td>&#8195;<italic>Primigravidae, n (%)</italic></td><td align="center">443 (16)</td><td align="center">477 (21)</td><td align="center">432 (21)</td><td align="center">251 (21)</td><td align="center">1603 (19)</td></tr><tr><td>&#8195;<italic>Low birth weight, n (%)</italic></td><td align="center">867 (31)</td><td align="center">1003 (44)</td><td align="center">672 (32)</td><td align="center">536 (44)</td><td align="center">3078 (37)</td></tr><tr><td colspan="6">(d) Malaria-based interventions, n (%)</td></tr><tr><td>&#8195;<italic>Child's family owns bed net</italic></td><td align="center">2160 (77)</td><td align="center">1528 (67)</td><td align="center">1983 (95)</td><td align="center">1040 (85)</td><td align="center">6711 (80)</td></tr><tr><td>&#8195;Child received antimalarial during past week</td><td align="center">314 (11)</td><td align="center">117 (5.2)</td><td align="center">50 (2.4)</td><td align="center">24 (2.0)</td><td align="center">505 (6.0)</td></tr><tr><td>&#8195;Child's house had indoor insecticide spraying</td><td align="center">22 (0.8)</td><td align="center">541 (24)</td><td align="center">na</td><td align="center">148 (12)</td><td align="center">711 (8.5)<xref ref-type="table-fn" rid="tblfn2">&#8224;</xref></td></tr><tr><td>&#8195;Mother took antimalarial during child's gestational period</td><td align="center">2616 (93)</td><td align="center">1109 (50)</td><td align="center">337 (16)</td><td align="center">1110 (91)</td><td align="center">5162 (62)</td></tr><tr><td colspan="6">(e) Genetic mechanisms of malaria protection, median (IQR)</td></tr><tr><td>&#8195;Mean predicted HbS allele frequency</td><td align="center">0.06 (0.05&#8211;0.06)</td><td align="center">0.03 (0.01&#8211;0.03)</td><td align="center">0.03 (0.03&#8211;0.03)</td><td align="center">0.07 (0.06&#8211;0.07)</td><td align="center">0.04 (0.03&#8211;0.06)</td></tr><tr><td>&#8195;Median predicted G6PDd allele frequency</td><td align="center">0.06 (0.05&#8211;0.09)</td><td align="center">0.15 (0.15&#8211;0.17)</td><td align="center">0.04 (0.04&#8211;0.05)</td><td align="center">0.10 (0.09&#8211;0.13)</td><td align="center">0.08 (0.05&#8211;0.14)</td></tr><tr><td colspan="6">(f) Climate of communities surveyed, median (IQR)</td></tr><tr><td>&#8195;<italic>Annual range of enhanced vegetation index (EVI)</italic></td><td align="center">0.29 (0.24&#8211;0.32)</td><td align="center">0.33 (0.22&#8211;0.40)</td><td align="center">0.25 (0.20&#8211;0.29)</td><td align="center">0.28 (0.18&#8211;0.34)</td><td align="center">0.28 (0.22&#8211;0.33)</td></tr><tr><td>&#8195;<italic>Annual mean of EVI for the year</italic></td><td align="center">0.22 (0.18&#8211;0.25)</td><td align="center">0.40 (0.32&#8211;0.47)</td><td align="center">0.39 (0.36&#8211;0.42)</td><td align="center">0.18 (0.16&#8211;0.20)</td><td align="center">0.29 (0.20&#8211;0.40)</td></tr><tr><td>&#8195;<italic>No. of days which EVI above annual mean</italic></td><td align="center">136 (120&#8211;160)</td><td align="center">88 (56&#8211;128)</td><td align="center">320 (168&#8211;384)</td><td align="center">208 (184&#8211;264)</td><td align="center">152 (120&#8211;200)</td></tr><tr><td>&#8195;<italic>No. of days for rainy season (corresponding to first and last day EVI above annual mean)</italic></td><td align="center">136 (120&#8211;152)</td><td align="center">128 (72&#8211;344)</td><td align="center">344 (296&#8211;352)</td><td align="center">216 (152&#8211;352)</td><td align="center">168 (120&#8211;344)</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><label>*</label><p><italic>P</italic>&#402;-HRP-2 testing not conducted as part of DHS survey protocol for Mozambique.</p></fn><fn id="tblfn2"><label>&#8224;</label><p>Information on insecticide spraying not collected as part of survey.</p></fn></table-wrap-foot></table-wrap>